Safety of high-dose-rate brachytherapy in patients with prostate cancer and inflammatory bowel disease: A case series

CONCLUSIONS: HDR brachytherapy appears to be a safe and tolerable treatment modality for patients with prostate cancer and IBD, with minimal acute and late GI and GU toxicity. These findings warrant multi-institutional validation due to small sample size.PMID:38584887 | PMC:PMC10993899 | DOI:10.5114/jcb.2024.135645

Source: Journal of Contemporary Brachytherapy - April 8, 2024 Category: Cancer & Oncology Authors: Horatio Thomas Jie Jane Chen Haitham Shaheen Ali Sabbagh Hasan Abdul-Baki Oi Wai Chau Nauman Malik Alan Ayoub Comron Hassanzadeh I-Chow Hsu Osama Mohamad Source Type: research